Cargando…
Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas
Cutaneous T-cell lymphomas (CTCL) are the most common primary lymphomas of the skin. We have previously identified thymocyte selection-associated high mobility group (HMG) box protein (TOX) as a promising drug target in CTCL; however, there are currently no small molecules able to directly inhibit T...
Autores principales: | Agrawal, Vibudh, Su, Mingwan, Huang, Yuanshen, Hsing, Michael, Cherkasov, Artem, Zhou, Youwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803922/ https://www.ncbi.nlm.nih.gov/pubmed/31554191 http://dx.doi.org/10.3390/molecules24193459 |
Ejemplares similares
-
Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis
por: Huang, Yuanshen, et al.
Publicado: (2014) -
Deep Docking: A Deep Learning Platform for Augmentation
of Structure Based Drug Discovery
por: Gentile, Francesco, et al.
Publicado: (2020) -
Higher thymocyte selection-associated high mobility group box (TOX) expression predicts poor prognosis in patients with ovarian cancer
por: Li, Sai, et al.
Publicado: (2022) -
TOX expression in cutaneous B-cell lymphomas
por: Schrader, Anne M. R., et al.
Publicado: (2016) -
Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma
por: Dulmage, Brittany O., et al.
Publicado: (2019)